Paradromics Turning Data Into Medicine
Austin, US Β· Founded 2015 Β· 124 employees on LinkedIn Β· 25 known investors
Paradromics develops a brain-computer interface (BCI) system, with FDA Breakthrough Device Designations for speech decoding and digital device control, and works with academic medical institutions on translational BCI research. The company builds implantable neurotechnology aimed at clinical applications.
Also known as Paradromics Β· Paradromics Inc.
Founders & leadership
Paradromics Turning Data Into Medicine was founded in 2015 by Matt Angle.
Investors Β· 25
Also in the syndicate Β· 4
Company profile
researched Aug 2026Paradromics is a neurotechnology company developing a high-data-rate platform for exchanging information between the brain and computers. Its lead product, the Connexus BCI, is an implantable brain-computer interface engineered to restore communication for people who have lost the ability to speak. The company positions the device as a platform technology, with successive generations intended to broaden the range of applications from brain-based therapeutics toward wider human-computer integration.
The company describes years of engineering work, safety testing and preclinical research preceding the Connexus BCI's first-in-human study, which follows FDA approval for clinical studies in humans. Paradromics also works with academic medical institutions on translational BCI research, aligning academic innovation with its own device platform. Founder and CEO Matt Angle frames brain interfaces as a complement to artificial intelligence, connecting computational algorithms with neural data.
Business model
Paradromics is developing a proprietary implantable medical device platform (Connexus BCI) intended for clinical use, advancing it through regulatory approval and human clinical studies, and collaborating with academic medical institutions on translational research.
Traction
The Connexus BCI received FDA approval for clinical studies in humans, and press coverage in mid-2026 reported the first clinical implantation of the company's first-generation brain-computer interface in a patient with impaired speech.
Latest developments
In June 2026, coverage reported the first-in-human wireless brain implant performed by physicians in Michigan. In July 2026, the company announced the appointment of William J. Marks, Jr., MD, MS-HCM as Chief Clinical Officer. Shares in the company are listed as available to accredited investors on the EquityZen secondary marketplace.
βΈFull profile β market position, technology, go-to-market, geography
Market position
Paradromics presents Connexus as the fastest brain-computer interface in the world and itself as bringing to market the first high-data-rate interface between brains and computers.
Emphasis on data rate and bandwidth of the neural interface, with the Connexus device described as the fastest BCI in the world and as a platform intended to scale across successive device generations.
Technology
A high-data-rate, wireless implantable brain-computer interface, marketed as the Connexus BCI, designed to record neural signals at high bandwidth and decode them for communication, including speech decoding and control of digital devices.
Go-to-market
People who have lost the ability to speak or to control digital devices due to neurological impairment, reached through clinical study sites and academic medical institutions.
Geography
Headquartered in Austin, Texas, United States; a first-in-human implant was reported at a clinical site in Michigan.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Non-dilutive funding Β· 2 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $797.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Timeline Β· 16
launches, deals, and filingsParadromics announced FDA approval to embed BCI software in personal devices, expanding BCI access to personal computing devices within the Connect-One clinical study.
Press announcements reported the appointment of William J. Marks, Jr., MD, MS-HCM as Chief Clinical Officer of Paradromics.
Press coverage reported that physicians in Michigan placed a first-in-human wireless brain implant in a woman with impaired speech, described as the first clinical implantation of the company's first-generation brain-computer interface.
Paradromics states its Connexus BCI was recently approved by the FDA for clinical studies in humans, enabling a first-in-human study following preclinical research and safety testing.
Paradromics received FDA IDE approval to conduct first-in-human clinical trials; press coverage described regulatory approval to test the BCI in a small trial assessing safety and efficacy for speech restoration.
Reported launch of a patient registry in advance of the company's human clinical trial.
Paradromics was accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot for innovative devices.
The Connexus BCI received a second Breakthrough Device Designation covering use by individuals with severe motor deficits to control computer devices.
Series A of $33 million intended to help launch the first-in-human clinical trial of the Connexus BCI.
$33M source β
The U.S. FDA granted the Connexus Brain-Computer Interface (also described as the Connexus Direct Data Interface) Breakthrough Device Designation, providing expedited review for transformative devices treating irreversibly debilitating conditions.
Seed round of $20 million led by Prime Movers Lab, following $10M in earlier private funding and $15M of public funding from NIH and DARPA.
$20M source β
As part of the Prime Movers Lab investment, Partner Dr. Amy Kruse joined the Paradromics board of directors.
Paradromics was awarded a $3.2 million Phase II SBIR grant from the NIH to develop high-density intracortical microelectrode arrays for clinical applications, including collaboration with Massachusetts General Hospital's Center for Neurotechnology and Neurorecovery.
$3.2M source β
In late 2019 Paradromics moved from developing core technology capabilities to building a marketable medical device, the Connexus Brain-Computer Interface.
After securing an NIH SBIR and a DARPA contract collectively worth about $15 million within its first two years, Paradromics raised venture funds in 2018.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- Paradromics Turning Data Into Medicineparadromics.com Β· web
- Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDAparadromics.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Paradromics Turning Data Into Medicine do?
- Paradromics develops the Connexus high-data-rate implantable brain-computer interface to restore communication for people unable to speak.
- Who founded Paradromics Turning Data Into Medicine?
- Paradromics Turning Data Into Medicine was founded by Matt Angle in 2015.
- Who are Paradromics Turning Data Into Medicine's investors?
- Paradromics Turning Data Into Medicine's investors include 15th Rock, Alpha Edison, Anthropy Partners, Capital Factory, CoastCap, Frontier Path VC, Fusion, Harmonix Fund and 13 more.
- Where is Paradromics Turning Data Into Medicine headquartered?
- Paradromics Turning Data Into Medicine is headquartered in Austin, US.